Tradestie Institutional Equity Comparison Engine
REVB vs KAVL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REVB Overall Edge
REVB Captures Institutional Edge (3โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Revelation Biosciences, Inc. Common Stock (REVB) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, REVB trades at 0.9x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus KAVL at N/M Forward P/E and -392.1% operating margin (-80.0% YoY). In options structure, REVB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against KAVL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
REVB
REVB 0.9x vs KAVL N/M Fwd P/E
Growth & Margin Winner
REVB
Op Margin 0.0% vs -392.1% ยท YoY +0.0% vs -80.0%
Momentum & Technical Winner
REVB
1Y +309.9% vs -83.9% ยท 52W Pos 71% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
REVB
NASDAQ
Revelation Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$3.50
-5.15% 1D
Market Cap
$2.1M
1M Return
-4.89%
1Y Return
+309.93%
Forward P/E
0.9x
Unified AI Score
44.6 / 100
HOLD
Tech 20.0
Fund 37.0
Flow 50.0
Mom 36.0
KAVL
NASDAQ
Kaival Brands Innovations Group, Inc
Retail-Nonstore Retailers
$0.14
-12.96% 1D
Market Cap
$1.8M
1M Return
-71.05%
1Y Return
-83.86%
Forward P/E
N/M
Unified AI Score
49.1 / 100
HOLD
Tech 40.0
Fund 49.0
Flow 50.0
Mom 63.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
REVB +309.93%
KAVL -83.86%
Spread: +71.84 pp (REVB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
REVB TTM Op. Margin: 0.0%
KAVL TTM Op. Margin: -392.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REVB vs KAVL. Trailing 12-month operating profitability (REVB 0.0% vs KAVL -392.1%) and valuation multiples (REVB 0.9x vs KAVL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | REVB | KAVL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1M | $1.8M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | 0.9x | N/M | Lower Multiple | REVB |
| Forward P/E Ratio Valuation | 0.9x | N/M | Lower Multiple | REVB |
| Revenue Growth (YoY) Growth | +0.0% | -80.0% | Higher Growth | REVB |
| Operating Margin (TTM) Profitability | 0.0% | -392.1% | Higher Margin | REVB |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -133.4% | -68.6% | Higher ROE | KAVL |
| 52-Week Range Position Momentum | 71% ($0โ$5) | 1% ($0โ$2) | Stronger Trend | REVB |
| Beta / 30D Volatility Risk Regime | 2.88ฮฒ ยท 101% Vol | 0.88ฮฒ ยท 244% Vol | Lower Realized Risk | REVB |
| Unified Institutional Score Composite Signal | 44.6 / 100 (HOLD) | 49.1 / 100 (HOLD) | Higher Composite | KAVL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full REVB vs KAVL Buy Guide
REVB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
KAVL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither REVB nor KAVL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.